On December 10th @ 11am PST / 2pm EST, the Canadian Treatment Action Council (CTAC) will be hosting an informative webinar with a survey to follow about the hep C treatment ombitasvir/paritaprevir/ritonavir and dasabuvir. The treatment is currently undergoing a CADTH Common Drug Review (CDR), which is now collecting patient input.
The survey that will follow the Canadian Treatment Action Council webinar is different from PHCN’s patient input survey. Please consider filling out both surveys.
Registration for the webinar is required. Email Adam Cook to register to attend or to get more information about the webinar.